Corticosteroid Treatment for Moderate Ulcerative Colitis

Introduction to Corticosteroid Therapy

• The European Crohn’s and Colitis Organisation recommends prednisolone 40 mg daily as the standard treatment for moderate ulcerative colitis, with a gradual reduction over 6-8 weeks 1, 2
• A dose of 40 mg has been shown to be more effective than 20 mg/day, with no additional benefit from doses above 40-60 mg/day 3, 4
• The American Gastroenterological Association suggests that the dose should be administered in a single daily intake, as it is as effective as divided doses and causes less adrenal suppression 1
• Treatment should be maintained for 6-8 weeks with a gradual reduction in dose 1, 2

Assessment and Adjustment of Therapy

• The response to corticosteroid treatment should be evaluated within the first 2 weeks to determine the need for therapy modification 5, 6
• If there is no adequate response after 2 weeks, consideration should be given to escalating to advanced therapies (biologics or small molecules) 3

Alternatives to Systemic Corticosteroids

• For patients who wish to avoid systemic corticosteroids, alternatives such as budesonide MMX 9 mg/day for 8 weeks may be considered 2, 7
• Beclometasone dipropionate 5 mg/day for 4 weeks is another option, which has been shown to be non-inferior to prednisolone in mild to moderate ulcerative colitis 8, 9

Important Considerations

Adverse Effects

• Approximately 50% of patients experience short-term adverse effects such as acne, edema, sleep disturbances, mood changes, glucose intolerance, and dyspepsia 2, 7
• Prolonged treatment with high doses of corticosteroids is not recommended due to the increased risk of adverse effects without additional benefit 3

Dependence on Corticosteroids

• Patients who require two or more cycles of corticosteroids in the last year or who become corticosteroid-dependent need therapeutic escalation with thiopurines, anti-TNF therapy, vedolizumab, or tofacitinib 2, 7
• Corticosteroids are not recommended for long-term maintenance due to their ineffectiveness for this indication and the significant adverse effects associated with their prolonged use 5, 6

Special Situations

• For severe crises requiring hospitalization, the recommended dose is methylprednisolone 60 mg IV daily or hydrocortisone 100 mg four times a day 10

Steroid Dosing and Management in Active Ulcerative Colitis

Initial Systemic Corticosteroid Regimen (Outpatient)

• For adults with moderate‑to‑severe active ulcerative colitis, start oral prednisone 40–60 mg once daily in the morning; this dose achieves remission in most patients while limiting excess adverse effects. 11
• Prednisone 40 mg daily is the standard dose endorsed by major gastroenterology societies for moderate ulcerative colitis. 11
• A dose of 40 mg is more effective than 20 mg daily, and increasing the dose above 60 mg does not provide additional clinical benefit. 11

Intravenous Corticosteroid Therapy for Hospitalized Acute Severe UC

• In hospitalized patients with acute severe ulcerative colitis, use intravenous methylprednisolone 40–60 mg/day (or hydrocortisone 100 mg every 6 hours) rather than higher steroid doses. [12][13]
• Meta‑regression of trials (baseline disease severity controlled) shows no correlation between corticosteroid dose (40–100 mg range) and risk of colectomy. [12][13]
• Assess clinical response within 3–5 days of initiation; continuing steroids beyond 7 days offers no benefit for non‑responders. [12][13]

Corticosteroid Taper Protocol

• Prednisone should be tapered gradually over 6–8 weeks to minimize relapse risk while limiting cumulative steroid exposure. 11
• The total taper duration—from the start of therapy to discontinuation—should be 6–8 weeks. 11

Safety and Adverse‑Effect Profile

• Approximately 50 % of patients experience short‑term corticosteroid‑related adverse effects (e.g., acne, edema, sleep disturbance, mood changes, glucose intolerance, dyspepsia). 11
• Corticosteroids should never be used for maintenance therapy; prolonged use is associated with infections, osteoporosis, cataracts, and increased mortality. 11

Steroid Dependency and Escalation to Steroid‑Sparing Therapy

• Patients who become steroid‑dependent should be escalated promptly to steroid‑sparing agents such as thiopurines, anti‑TNF biologics, vedolizumab, or tofacitinib. 11

Oral Prednisone Failure in Moderate‑to‑Severe Ulcerative Colitis

Failure Rates and Need for Escalation

• Approximately 30–50 % of adults with moderate‑to‑severe ulcerative colitis do not achieve remission with oral prednisone, and among those who initially respond, about 45 % become steroid‑dependent or require escalation to advanced therapies within one year. 14
• Oral prednisone at 40–60 mg daily induces clinical remission in only 50–70 % of patients with moderate‑to‑severe disease, leaving 30–50 % with primary treatment failure. 14

Early Clinical Predictors of Steroid Non‑Response

• Lack of clinical improvement by day 14 of oral prednisone therapy should prompt consideration of escalation to biologic agents or hospital admission. 14
• Patients who require ≥2 courses of corticosteroids within a single year, or who become steroid‑dependent, should be escalated to thiopurines, anti‑TNF agents, vedolizumab, or tofacitinib. 14

Risk Factors Guiding Early Biologic Initiation

• Extensive disease (pancolitis) rather than left‑sided or distal involvement.
• Severe disease activity (Mayo score ≥ 6).
• Baseline hemoglobin ≤ 11 g/dL.
• Prior failure of one oral corticosteroid course.
• Need for > 14 days of oral prednisone to achieve any response.

Maintenance Therapy Recommendations

• Oral or systemic corticosteroids should never be used for maintenance of ulcerative colitis because they are ineffective for long‑term control and are associated with significant adverse effects such as infections, osteoporosis, and cataracts. [14][16]

Adverse Effects and Common Pitfalls

• Continuing oral prednisone beyond 2 weeks without clinical improvement delays necessary treatment escalation and increases the risk of complications. 14
• Prolonged high‑dose corticosteroid therapy yields diminishing therapeutic returns while raising the likelihood of infectious, metabolic, and surgical complications. 14
• Approximately 50 % of patients experience short‑term adverse effects (e.g., acne, peripheral edema, sleep or mood disturbances, glucose intolerance, dyspepsia) even when dosed appropriately. [14][16]

Steroid Therapy Recommendations for Ulcerative Colitis

Outpatient Management of Moderate‑to‑Severe UC

• Initial oral prednisolone dose: Begin adults with moderate‑to‑severe ulcerative colitis on prednisolone 40 mg once daily in the morning, followed by a gradual taper over a total of 6–8 weeks to complete discontinuation. This regimen balances efficacy with safety and avoids the increased adverse effects seen with higher doses. 17
• Tapering schedule: A taper that extends over 6–8 weeks is essential; accelerating the taper is linked to a higher risk of early disease relapse. The full taper period, not just the duration of full‑dose therapy, should be adhered to. 18

Inpatient Management of Acute Severe UC

• Intravenous corticosteroid dosing: Hospitalized patients with acute severe ulcerative colitis should receive intravenous methylprednisolone 40–60 mg per day (or hydrocortisone 400 mg per day in divided doses). Doses above this range do not improve outcomes and increase toxicity. [17][19]18
• Avoidance of higher IV doses: Escalating IV corticosteroid doses beyond 60 mg/day provides no additional clinical benefit and is associated with more adverse effects. [17][19]

Rescue Therapy for Steroid‑Refractory Acute Severe UC

• Second‑line rescue agents: Patients who do not respond to the standard IV corticosteroid regimen within 3–5 days should be escalated to rescue therapy with infliximab or cyclosporine. These agents improve short‑term outcomes and reduce the need for emergent surgery. [17][19]

Transition to Steroid‑Sparing Therapy

• Indications for escalation: Individuals requiring two or more corticosteroid courses within a year, or who become steroid‑dependent, should be switched to steroid‑sparing medications. Recommended options include thiopurines (azathioprine 1.5–2.5 mg/kg/day or mercaptopurine 0.75–1.5 mg/kg/day), anti‑TNF agents, vedolizumab, ustekinumab, or tofacitinib. These therapies provide long‑term disease control without the cumulative harms of steroids. [17][19]